Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Porosome Therapeutics Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are assigned to a single distinct examiner, ROGERS, ERIC JASON. Despite the involvement of only 1 distinct examiner, the portfolio's pending actions are distributed across 2 distinct art units. ROGERS, ERIC JASON is the busiest examiner for the company, overseeing 2 busiest examiner pending actions.
The distribution of 2 pending office actions across 2 distinct art units under a single examiner is a specific concentration. It suggests that ROGERS, ERIC JASON is reviewing applications that, while technically distinct enough to be in 2 distinct art units, fall under his specific expertise. For the applicant, this means that a consistent examination style will be applied across these different technical classifications. The 2 pending office actions represent the entirety of the company's current workload at the USPTO.
Practitioners should focus on the specific preferences and past rulings of ROGERS, ERIC JASON, as he holds total influence over the 2 pending office actions. The involvement of 2 distinct art units suggests the technology has multiple facets, yet the reliance on 1 distinct examiner simplifies the negotiation process. Managing these 2 pending actions requires a strategy tailored to this specific examiner's approach within the Biotechnology & Pharmaceuticals sector.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROGERS, ERIC JASON | 2 | 56.9% | +33.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18584830 | FUNCTIONAL POROSOME MANIPULATION | ROGERS, ERIC JASON | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18584830 | FUNCTIONAL POROSOME MANIPULATION | ROGERS, ERIC JASON | — |
| 18446111 | FUNCTIONAL POROSOME MANIPULATION | ROGERS, ERIC JASON | — |
| Art Unit | Apps |
|---|---|
| 1638 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18584830 | FUNCTIONAL POROSOME MANIPULATION | ROGERS, ERIC JASON | 1638 | §101§102§103§112DP | Final Rejection | — | Pending | Feb 22, 2024 |
| 18446111 | FUNCTIONAL POROSOME MANIPULATION | ROGERS, ERIC JASON | 1638 | §103§112DP | Non-Final OA | — | Pending | Aug 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPorosome Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Eric Jason Rogers has the most, with 2 of Porosome Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
